首页 > avivasysbio > avivasysbio/SPRED2 Antibody - C-terminal region (ARP60369_P050)/100 ul/ARP60369_P050

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

avivasysbio/SPRED2 Antibody - C-terminal region (ARP60369_P050)/100 ul/ARP60369_P050

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

ARP60369_P050

品牌：

avivasysbio

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Hepatocytes derived from human induced pluripotent stem (hiPS) cells using the Cellartis iPS Cell to Hepatocyte Differentiation System are an alternative to primary hepatocytes, as they exhibit sufficient expression levels of drug-metabolizing enzymes and transporters and demonstrate stable functionality over time in culture. In addition, hiPS cell-derived hepatocytes can provide an accurate reflection of the metabolic diversity observed in the human population.Hepatocytes derived from human induced pluripotent stem (hiPS) cells using the Cellartis iPS Cell to Hepatocyte Differentiation System are an alternative to primary hepatocytes, as they exhibit sufficient expression levels of drug-metabolizing enzymes and transporters and demonstrate stable functionality over time in culture. In addition, hiPS cell-derived hepatocytes can provide an accurate reflection of the metabolic diversity observed in the human population. The Cellartis iPS Cell to Hepatocyte Differentiation System provides a complete solution for generating functional, hiPS cell-derived hepatocytes within three weeks.The process of generating hiPS cell-derived hepatocytes begins with the directed differentiation of hiPS cells into Definitive Endoderm (DE) cells that are then differentiated further into hepatocytes. The complete system provides media and ready-to-use coatings for each step of the iPS-cell-to-hepatocyte differentiation protocol. Starting with approximately 3 x 106 undifferentiated hiPS cells, this system yields 5 x 106 hepatocytes, equivalent to a confluent monolayer of 50 cm2. This do-it-yourself system offers a solution for the consistent production of assay-ready cells from patient-derived cells or from Cellartis brand iPS cell lines—enabling highly reproducible results.Hepatocytes obtained with the Cellartis iPS Cell to Hepatocyte Differentiation System express major hepatic markers and show relevant CYP enzyme activities based on the genetic background of the original hiPS cells from which they were derived. In addition, these freshly differentiated hepatocytes are functionally stable for a longer timeframe compared to cryopreserved primary hepatocytes, enabling prolonged experiments such as long-term toxicity assays or viral infection studies. Cellartis Hepatocyte Maintenance Medium (Cat. # Y30051) is recommended for long-term maintenance of hiPS cell-derived hepatocytes. More Less

avivasysbioVytas P. Ambutas- 董事会主席

Ambutas先生是一家多元化的工业控股公司National Material LP的总法律顾问，秘书兼法律和行政副总裁。Ambutas先生是Tang Industries，Inc.的总法律顾问，Tang Industries，Inc.是一家多元化控股公司，包括工业，制药，家具和房地产控股公司，并担任高强度碳素钢加工商Nacme Steel Processing，LLC的董事，以及Key Colony，Inc.，果汁产品的制造商和分销商。Ambutas先生从1980年至1992年曾从事私人执业。Ambutas先生拥有芝加哥洛约拉法学院的法学博士学位和西密歇根大学的学士学位。

朱利安- 董事会成员

朱利安·袁（Julian Yuan）是联合创始人兼董事会成员。袁先生还是英杰华生物科技公司的联合创始人和董事会成员。袁先生自1983年成立以来，一直担任Progressive Group Inc.（PGI）的总裁兼首席执行官。PGI是其中之一。台湾最大的医疗器械经销商。袁先生是一位企业家，在生物科学产品，医疗设备和仪器的管理和营销方面拥有22年的经验。袁先生于1979年在台湾中原大学获得化学学士学位。

Patrick Liang- 董事会成员

梁先生现任唐实业有限公司中国业务董事总经理兼唐投资集团（中国）有限公司总裁。之前，梁先生曾任中国材料有限公司总经理，SKD中国副总裁，以及Irvine Networks业务开发副总裁兼SCA咨询管理顾问。梁先生拥有芝加哥大学布斯商学院的工商管理硕士学位和双学位，并拥有西北大学的经济学学士学位和国际研究学士学位。